ZLZhuoyuan Lin

Zhuoyuan Lin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhuoyuan Lin has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Chuanfan Zhong

    Zhujiang Hospital, Southern Medical University, Guangzhou, China

    2 shared publications
  • Jianming Lu

    Department of Andrology, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou, China

    2 shared publications
  • Qinwei Liu

    Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Key Laboratory of Urology, Guangzhou Institute of Urology, Guangzhou, China

    2 shared publications
  • Zhouda Cai

    Department of Andrology, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou, China

    2 shared publications
  • Biao Hu

    Department of Clinical Medicine The Second Clinical School of Guangzhou Medical University Guangzhou China

    1 shared publication
  • Changsheng Zhao

    College of Polymer Science and Engineering State Key Laboratory of Advanced Polymer Materials Sichuan University Chengdu China

    1 shared publication

Latest Publications

  • Open Access

    Silencing of SLC6A1 Enhanced Cell Apoptosis in Prostate Cancer Through a Mitochondrial Mechanism

    by Chaojiang Chen, Ranting Wang, Zhuoyuan Lin, Jianxin Li, Yu Zheng

    Objective: The present study aims to elucidate the molecular mechanisms underlying the association between solute carrier family 6 member 1 (SLC6A1) and the aggressive progression of prostate cancer, with a particular emphasis on its relationship with mitochondrial function. Methods: To evaluate mitochondrial function, we detected mitochondrial membrane potential, adenosine triphosphate (ATP) production, intracellular reactive oxygen species (ROS) levels, and mitochondrial morphology in prostate cancer cell lines. Western blot was used to detect apoptosis‐related proteins. Gene set enrichment analysis (GSEA) was performed using The Cancer Genome Atlas (TCGA) prostate cancer dataset. Results: Our findings indicated that silencing of SLC6A1 decreased mitochondrial membrane potential and ATP production while increasing intracellular ROS levels, accompanied by Bax upregulation and activation of the caspase pathway. Furthermore, GSEA results suggested that low SLC6A1 expression might trigger cell apoptosis via mitochondrial disruption mediated by the interaction between potassium and calcium channels. Conclusion: These results highlighted the role of SLC6A1 in mitochondrial dysfunction associated with cell apoptosis in prostate cancer cells. This study has provided further insights into the molecular mechanisms of advanced prostate cancer and potential therapeutic targets.

  • Aberrant Super-Enhancer Landscape in Enzalutamide-Resistant Prostate Cancer Cells

    by Chao Cai, Qinwei Liu, Haoran Shan, Chuanfan Zhong, Guidong Chen, Zhouda Cai, Yu Zheng, Jianming Lu, Jiaojiao Tang, Zhuoyuan Lin

    Background: Castration-resistant prostate cancer (CRPC), which has developed resistance to next-generation antiandrogens, such as enzalutamide (Enz), is a lethal disease. Furthermore, transcriptional regulation by super enhancers (SEs) is crucial for the growth and spread of prostate cancer, as well as drug resistance. The functions of SEs, a significant class of noncoding DNA cis-regulatory elements, have been the subject of numerous recent studies in the field of cancer research. Materials and Methods: The goal of this research was to identify SEs associated with Enz resistance in C4-2B cells using chromatin immunoprecipitation sequencing and cleavage under targets and tagmentation (CUT&Tag). Using HOMER analysis to predict protein/gene-binding motifs, we identified master transcription factors (TFs) that may bind to SE sites. Using small interfering RNA, WST-1 assays, and qRT-PCR, we then confirmed the associations between TFs of SEs and Enz resistance. Results: A total of 999 SEs were screened from C4-2B EnzR cells in total. Incorporating analysis with RNA-seq data revealed 41 SEs to be strongly associated with the promotion of Enz resistance. In addition, we finally predicted that master TFs bind to SE-binding regions. Subsequently, we selected zinc finger protein 467 (ZFP467) and SMAD family member 3 to confirm the functional connections of master TFs with Enz resistance through SEs (ZNF467). Conclusions: In this study, SMAD3 and ZNF467 were found to be closely related to Enz-resistant CRPC. Our research uncovered a sizable group of SEs linked to Enz resistance in prostate cancer, dissected the mechanisms underlying SE Enz resistance, and shed light on potential clinical uses for SEs.


  • Open Access

    Dietary magnesium is able to influence the relationship between vitamin C and estimated glomerular filtration rate: A cross‐sectional study

    by Zheng‐Yang Lin, Yong‐Yi Liang, Ru Wang, Biao Hu, Wen‐Ju He, Jun‐Kui Li, Zi‐Ang Ding, Zhuo‐Yuan Lin, Shi Zhang

    The estimated glomerular filtration rate (eGFR) is a comprehensive index that is widely used to assess renal function. Although studies have confirmed a correlation between eGFR and dietary vitamin C, the impact of varying levels of vitamin C on eGFR remains unclear. Additionally, the interaction between dietary magnesium intake and vitamin C concentration on eGFR is not well understood. As such, the objective of this study was to investigate the relationship between dietary magnesium intake and vitamin C in relation to eGFR. This study analyzed the data of consecutive NHANES from 2005 to 2018. We included 17,633 participants aged 20 or older and used multiple linear regression analysis to evaluate the relationship between dietary vitamin C and eGFR. Dietary Mg intake from experimental data was dichotomized into a low dietary Mg intake group (≤254 mg/day) and a normal dietary Mg intake group (>254 mg/day). To evaluate the impact of dietary magnesium intake on eGFR, a multivariable linear regression was conducted utilizing an interaction test between dietary vitamin C and eGFR. We discovered a positive association between dietary vitamin C content and eGFR. The relationship between dietary vitamin C levels and eGFR differed between individuals with low Mg intake and those with normal Mg intake (β: 2.96 95% CI:1.63 ~ 4.29 vs. β: 1.05 95% CI: −0.15 to 2.25), and the positive association of high dietary vitamin C content with eGFR was stronger in the low Mg intake group. Furthermore, we observed that dietary magnesium intake significantly altered the positive association between dietary vitamin C and eGFR (interaction value of 0.020). Our experimental study revealed that the interaction between dietary magnesium and dietary vitamin C can significantly impact eGFR. This finding carries significant implications for the treatment of diseases resulting from abnormal eGFR, as well as the selection of clinically relevant drugs.


  • Open Access

    A prognostic signature consisting of N6-methyladenosine modified mRNAs demonstrates clinical potential in prediction of biochemical recurrence and guidance on precision therapy in prostate cancer

    by Jianming Lu, Jiahong Chen, Zhuoyuan Lin, Qinwei Liu, Chuanfan Zhong, Zhouda Cai, Zhenyu Jia, Weide Zhong, Yingke Liang, Chao Cai


  • Open Access

    Abstract LB032: CXCR7 drives prostate cancer growth through AURKA activation

    by Galina Gritsina, Zhuoyuan Lin, Ka Wing Fong, Xiaodong Lu, Changsheng Zhao, Jindan Yu

    Prostate cancer (PCa) is the most commonly diagnosed cancer among males in the United States. The mainstay treatment for metastatic PCa patients is androgen-deprivation therapies, including high-affinity androgen receptor antagonists, such as enzalutamide. Unfortunately, most patients develop resistance and relapse with castration-resistant PCa (CRPC). We have previously reported up-regulation of CXCR7, an atypical chemokine receptor, in CRPC. CXCR7 interacts with beta-arrestin (ARRB2), a cytoplasmic scaffold protein, and translocates to the cytoplasm to induce signal transduction and PCa progression. However, much remains to be known regarding CXCR7-driven downstream signaling and its therapeutic targeting in advanced PCa. To unveil CXCR7-downstream signaling, we utilized RNA-seq to profile gene expression. Gene ontology analyses revealed remarkable enrichment of CXCR7-regulated genes in G2/M cell cycle progression. Comprehensive phospho-proteomics analysis of CXCR7-knockdown PCa cells showed markedly reduced phosphorylation of AURKA substrates. AURKA, a serine/threonine-protein kinase, is a key regulator of mitosis and G2/M progression and is frequently upregulated in CRPC and the late-stage neuroendocrine PCa (NEPC). Activated AURKA experiences autophosphorylation and phosphorylates downstream substrates, e.g., TACC3, that mediate proper cell division. Immunoblotting confirmed that CXCR7 depletion reduces phosphorylation of AURKA and TACC3. Co-immunoprecipitation revealed protein-protein interaction between CXCR7 and AURKA, which is mediated by ARRB2. Accordingly, ARRB2-knockdown similarly inhibits AURKA phosphorylation and arrests cell proliferation. Immunofluorescence coupled with confocal imaging demonstrated that CXCR7 is packed into clathrin-coated vesicles and locates in the plasma membrane, cytoplasm, and perinuclear Golgi complex, which surrounds the centrosomal AURKA and ARRB2. We found that CXCR7 translocates to the Golgi complex along microtubule-dependent trafficking. Finally, we found that pharmacological inhibitors of AURKA abolish CXCR7-driven PCa cell proliferation in vitro and tumor growth in vivo. Conclusions: Our results describe for the first time that the CXCR7-ARRB2 complex interacts with AURKA and promotes its activation. Our data suggest that AURKA-targeting is a promising therapeutic strategy for CRPC and NEPC with CXCR7 up-regulation. Citation Format: Galina Gritsina, Zhuoyuan Lin, Ka Wing Fong, Xiaodong Lu, Changsheng Zhao, Jindan Yu. CXCR7 drives prostate cancer growth through AURKA activation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB032.

  • Open Access

    Tumor Suppressor Role and Clinical Significance of the FEV Gene in Prostate Cancer

    by Yu-Xiang Liang, Ying-Ke Liang, Zhi-Hao Zou, Yang-Jia Zhuo, Jian-Heng Ye, Xue-Jin Zhu, Zhou-Da Cai, Zhuo-Yuan Lin, Ru-Jun Mo, Shu-Lin Wu, et al.

    Background. In our previous research, we developed a 32-gene risk index model that may be utilized as a robust prognostic method for predicting prostate cancer (PCa) recurrence after surgery. Among the 32 genes, the Fifth Ewing Variant (FEV) gene was one of the top downregulated genes in relapsed PCa. However, current understanding of the FEV gene and its involvement in PCa is limited. Methods. FEV mRNA expression was analyzed and correlated to clinical outcomes in PCa patients who underwent prostatectomy at the Massachusetts General Hospital. Specimens from tissue microarray (TMA) including 102 prostate cancer patients were analysis for the expression of FEV. Meanwhile, FEV expression profiles were also assessed in PCa cell lines and in BPH-1 prostate epithelial cells using western blotting and quantitative reverse transcription-PCR (qRT-PCR). Furthermore, we transfected LNCaP and PC-3 cells with either an empty vector or full-length FEV gene and performed in vitro cell functional assays. The part FEV plays in tumor xenograft growth was also assessed in vivo. Results. Of the 191 patients included in this study base on the DASL dataset, 77 (40.3%) and 24 (13.6%), respectively, developed prostate-specific antigen (PSA) relapse and metastasis postradical prostatectomy. Significant FEV downregulation was observed in PCa patients showing PSA failure and metastasis. The protein expression of FEV was significantly negatively correlated with the Gleason score and pathological stage in prostate cancer tissues. Similarly, FEV expression significantly decreased in all PCa cell lines relative to BPH-1 (all ). Functional assays revealed that FEV expression markedly inhibited PCa cell growth, migration, and invasion, which in turn significantly repressed the growth of tumor xenografts in vivo. Conclusion. The results of this study suggest an association between downregulated FEV expression and PSA relapse in PCa patients. In addition, FEV may act as a tumor suppressor in PCa.


  • Open Access

    The effect of octreotide on postprandial antral motility in patients with idiopathic gastroparesis

    by MC Edmunds, Jd Chen, Z Lin, RW McCallum